Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. | LitMetric
Galderma Research & Development, 2400 route des Colles, 06410 Biot, France.
Published: December 2008
AI Article Synopsis
Article Abstract
International guidelines recommend the combination of retinoids (e.g. adapalene, tazarotene) and benzoyl peroxide for treating acne because of their complementary mechanisms of action. A new fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide (BPO) 2.5% (adapalene/BPO*) is an effective acne treatment and offers the advantage of a once daily application. This paper reports the results of a cumulative irritancy study in healthy volunteers comparing adapalene/BPO to adapalene 0.1% and BPO 2.5% applied separately, BPO 10% gel, tazarotene 0.1% gel and the gel vehicle as a control.There was no significant difference between the mean cumulative irritation index (MCII) for adapalene/BPO and any test product except tazarotene 0.1% gel, which had a significantly greater MCII than all other test products (p < 0.05). This study showed that adapalene/BPO as a fixed-dose combination is as well tolerated as BPO 2.5% gel alone or adapalene 0.1% gel alone in terms of cumulative irritancy.*Epiduo, Galderma S.A.
Topical clindamycin phosphate/adapalene/benzoyl peroxide (CAB) gel is approved for treating acne in patients 12 and older, and post hoc analyses examined its effectiveness in younger patients with acne.
Data from two studies showed that CAB significantly improved treatment success and reduced acne lesions in adolescents compared to a vehicle gel, with 51.5% of treated adolescents achieving success versus 24.9% with the vehicle.
The CAB gel was generally well tolerated, with most adverse events being mild to moderate, and it was effective for younger children as well, with significant lesion reductions observed in all treated children.
A study was conducted to evaluate a combination gel containing adapalene 0.1% and clindamycin 1% for treating moderate acne, comparing its effectiveness to each medication used alone.
Results showed that the combination gel significantly reduced acne lesions by 66.85% after 12 weeks, outperforming adapalene (50.82%) and clindamycin (57.61%).
The combination gel was well tolerated and resulted in more participants achieving a 2-grade improvement in acne severity, indicating it is a more effective treatment option than the individual monotherapies.
Acne is a common skin condition that causes both inflammatory and non-inflammatory lesions, affecting areas like the face and back, and can lead to scarring and mental health issues, particularly in severe cases.
The study aims to evaluate the effectiveness and safety of both non-systemic medications and non-pharmacological treatments for acne vulgaris.
Out of 733 examined studies, only six high-quality reviews were included in the analysis, covering over 40,000 individuals with acne and over 1,300 with acne scars, presenting a comprehensive evidence base.
Purpose: Acne is a chronic inflammatory skin condition affecting mainly teenagers and adults as well. Guidelines recommend retinoids as a first-line treatment for mild-to-moderate acne. However, dermocosmetics in adjunct could potentially improve efficacy and tolerability.
